Why it matters
IMAGIO will leverage interventional oncology in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and affordable care pathways for three disease states: liver cancer, lung cancer and sarcoma. In IMAGIO, top innovators in MedTech and Pharma and expert academic clinical centres will mature the next-generation IO imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials. IMAGIO will deliver both the technology and the critical mass of early evidence to make IO part of the standard clinical care pathway to cancer treatment in Europe by 2030. The solution concept relies on the development and integration of key enabling imaging technologies and approaches in four multimodal care pathways.
What ECPC does
ECPC will have a key role in the dissemination of project results, and the identification of policy goals, towards patient empowerment. The planning and coordination of these activities will be described in a dissemination and communication strategy (D7.1), that will ensure consistency across various communication platforms. In addition, promote IMAGIO and its results to its patient community and policy makers, acting in synergy with the other patient organizations in IMAGIO.
This project is supported by the Innovative Health Initiative Joint Undertaking (JU) under grant agreement No 101112053. The JU receives support from the European Union’s Horizon Europe research and innovation programme and life science industries represented by COCIR, EFPIA / Vaccines Europe, EuropaBio and MedTech Europe.